Company

Noema Pharma AG

Noema Pharma develops treatments for central nervous system conditions, including neurological disorders.

About

Founded in 2019 and based in Basel, Switzerland, Noema Pharma develops therapies for CNS conditions, including seizures related to Tuberous Sclerosis Complex, Trigeminal Neuralgia pain, and Tourette Syndrome. Its founders are George Garibaldi and Luigi Costa, and Ilise Lombardo is CEO. In December 2024, the company raised CHF 103.000 mn in Series B funding, with participation from Forbion, Gilde Healthcare Partners, and Invus.

4Funding rounds

10Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in